All News
Clinical and Genetic Effects of Neuropsychiatric Lupus
The clinical features and genetic abnormalities of neuropsychiatric systemic lupus erythematosus shows that NPSLE often means more severe lupus and more organ involvement beyond the central nervous system.
Read Article
REPLENISH - Secukinumab Works in Polymyalgia Rheumatica
Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab in adults with polymyalgia rheumatica (PMR).
Read Article
Colchicine Ineffective in Long COVID
Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory markers.
Read Article
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have benefits beyond glycemic control, including cardioprotective and nephroprotective effects, with modest weight loss.
Read Article
Single center study ANCA-assoc. vasculitis. From 78 pts had poor outcomes (16 ESKD, 15 deaths). Elevated BUN was a risk factor (adj HR 1.07). Risk factors for ESKD were baseline BUN & WBC. Risks for death included CV Dz (HR 8.7), NLR (1.04) &anti-PLt Rx (HR 6.8) https://t.co/QQrDmja0zo
Dr. John Cush RheumNow ( View Tweet)
💬A JAKi CHAT: Shared Decision-Making in RA
Dr. Curtis and Dr. Winthrop discuss approaches to patient conversations on risk with uncontrolled RA and treatment considerations, including JAKi safety. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/YchKj5sZgB https://t.co/uchLGUuNH7
Dr. John Cush RheumNow ( View Tweet)
5–10% of axSpA [ts jave comorbid IBD. Southern Swedish study 152 (r- & nr-) axSpA pts found elevated fecal calprotectin (≥ 50 mg/kg) & this was assoc. w/ more damage w/ higher mSASSS values for all axSpA (adj OR 2.2) & in r-axSpA (adj OR 2.9) https://t.co/Hi1lE4so1r https://t.co/YYCGYYasfL
Dr. John Cush RheumNow ( View Tweet)
6-week intensive smoking cessation prg studied in 94 RA daily smokers in remission or low Dz activity (DAS28-CRP=2.9). At 3 mos the intervention group had higher cessation rates; but had no effect on EULAR responses, TJC, or CRP (result actually favoured the controls) https://t.co/HPJYeyPCPQ
Dr. John Cush RheumNow ( View Tweet)
NEW EULAR POSTER: Real-world treatment patterns across the first 12 months of first-line advanced therapy in patients with PsA Compare treatment switching across first-line MOAs and treatments. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/KlmYY7OPqU https://t.co/gciMXz90Zo
Dr. John Cush RheumNow ( View Tweet)
From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect:
• KOL videos
• Clinical trial highlights
• Daily faculty recaps
• Live streaming
#ACR25 #Rheumatology #ClinicalTrials https://t.co/IdH5HIQAQX
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Obinutuzumab for Active Lupus Nephritis
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
https://t.co/WbpATY86BY https://t.co/zRONkCUtIx
Dr. John Cush RheumNow ( View Tweet)
DERM on RheumNow (October 2025)
Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor https://t.co/bIK3e8sL45
Dr. John Cush RheumNow ( View Tweet)
Meniscal tears - Systematic review of 46 studies
- Incidence of 66 per 100,000
- Annual cost of 5 billion to US healthcare
- Trend to preserve the meniscus, do less removal, more preservation
- Biologic Rx (platelet-rich plasma & stem cell Rx) inconclusive results https://t.co/IPyRFad9GX
Dr. John Cush RheumNow ( View Tweet)
Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen.
Recommendation based on TULIP-SC Phase III trial. https://t.co/VRUycfLRtf https://t.co/O7cQfkb8BU
Dr. John Cush RheumNow ( View Tweet)
12 yr study of 115 Systemic Sclerosis pts shows Finger-to-palm distance (tip 4th finger to distal palmar crease) may be a useful tool for predicting the progression of skin thickening and the development of digital ulcers in the early stages of severe SSc https://t.co/brCEz5Fqac https://t.co/tiVBdfH39q
Dr. John Cush RheumNow ( View Tweet)
UK National Joint Registry study of 1.5 million TKR and THA (2010 to 2022); trends show median Length of hosp stay (LOS) decreased from 4.3d to 2.75 d for THR; & from 4.35d to 2.9d for TKR; & from 3.2d to 1.9d for UKR (unilat. knee replacement). Longer LOS with comorbidity, https://t.co/DNBZTPFRsl
Dr. John Cush RheumNow ( View Tweet)
Phase 3b/4 head-to-head SELECT-SWITCH study tested Humira vs Rinvoq in 492 RA MTX pts failing a TNFi then Rx w/ ADA vs UPA x12 wks. UPA > ADA w/ DAS28-CRP < 3.2 (43% vs 22%; p<0.001) and also for DAS28-CRP < 2.6 (28% vs 14%). No new safety signals seen.https://t.co/EAJ9GglMjv https://t.co/uHTsdTPpWP
Dr. John Cush RheumNow ( View Tweet)
Study from Czech ATTRA registry of 8,543 RA pts 641 (7.5%) met criteria for D2T-RA & 1,825 achieved remission (21%). D2T-RA predicted by machine learning models (accuracy 0.606–0.747, AUC 0.656–0.832). Predictors included CDAI, DAS28-ESR, TJC, HAQ, CRP, steroids https://t.co/PqgKzKhM6h
Dr. John Cush RheumNow ( View Tweet)
30% of RA pts have non-alcoholic fatty liver disease (NAFLD). In 170 pts on MTX or biologics (TNFi, IL-6i)- NAFLD was found in 36%. MTX & biologics were not linked to NAFLD or fibrosis -- BUT was signif assoc w/ metabolic syndr, BMI, Waist, ALT, and AST (all p < .001) https://t.co/MpkxjHEbxK
Dr. John Cush RheumNow ( View Tweet)
Bad Actor Cofactor (10.17.2025)
Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more
https://t.co/zDDLwwRSy9 https://t.co/2S8jPOY0Be
Dr. John Cush RheumNow ( View Tweet)
